Comparative Analysis of Mutation in the Buccal Epithelium and Blood in Patients with Lung Cancer and Healthy People

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Lung cancer is one of the leading causes of cancer death. Finding new methods for the early and accurate diagnosis of lung cancer is critical for effective treatment. We have shown that patients with lung cancer have more mutations in the FLT3, PDGFRA, KDR, PIK3CA, HRAS, FGFR3 genes in the buccal epithelium than people without diagnosed lung cancer. Thus, study of molecular alterations may be used as a method for the accurate diagnosis of lung cancer in the early stages of investigational procedure.

Full Text

Restricted Access

About the authors

O. V. Serzhantova

Voronezh Regional Clinical Oncological Dispensary; Voronezh State University

Email: gureev@bio.vsu.ru
Russian Federation, Voronezh; Voronezh

A. G. Novikova

Voronezh Regional Clinical Oncological Dispensary; Voronezh State University

Email: gureev@bio.vsu.ru
Russian Federation, Voronezh; Voronezh

A. A. Mikhailov

Voronezh Regional Clinical Oncological Dispensary

Email: gureev@bio.vsu.ru
Russian Federation, Voronezh

I. P. Moshurov

Voronezh Regional Clinical Oncological Dispensary

Email: gureev@bio.vsu.ru
Russian Federation, Voronezh

A. P. Gureev

Voronezh State University

Author for correspondence.
Email: gureev@bio.vsu.ru
Russian Federation, Voronezh

References

  1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ “НМИЦ радиологии” Минздрава России 2020. 252 с.
  2. Wadowska K., Bil-Lula I., Trembecki Ł., Śliwińska-Mossoń M. Genetic Markers in Lung Cancer Diagnosis: A Review // Int. J. Mol. Sci. 2020. V. 21. № 13. https://doi.org/10.3390/ijms21134569
  3. Rodionov E.O., Tuzikov S.A., Miller S.V. et al. Methods for early detection of lung cancer (review) // Sib. J. Oncology. 2020. V. 19. № 4. P. 112–122. https://doi.org/10.21294/1814-4861-2020-19-4-112-122
  4. Nanavaty P., Alvarez M.S., Alberts W.M. Lung cancer screening: advantages, controversies, and applications // Cancer Control. 2014. V. 21. № 1. P. 9–14. https://doi.org/10.1177/107327481402100102
  5. Hubers A.J., Prinsen C.F., Sozzi G. et al. Molecular sputum analysis for the diagnosis of lung cancer // Br. J. Cancer. 2013. V. 109. № 3. P. 530–537. https://doi.org/10.1038/bjc.2013.393
  6. Ganeev A.A., Gubal A.R., Lukyano G.N. et al. Analysis of exhaled air for early-stage diagnosis of lung cancer: opportunities and challenges // Russ. Chemical Reviews. 2017. V. 87. № 9. P. 904–921. https://doi.org/10.1070/RCR4831
  7. Sidransky D. The oral cavity as a molecular mirror of lung carcinogenesis // Cancer Prev. Res. (Phila). 2008 V. 1. № 1. P. 12–14. https://doi.org/10.1158/1940-6207.CAPR-08-0093
  8. Bhutani N., Burns D.M., Blay H.M. DNA Demethylation dynamics // Cell. 2011. V.146. № 6. P. 866–872. https://doi.org/10.1016/j.cell.2011.08.042
  9. Kömerik N., Yüce E., Calapoğlu N.S. et al. Oral mucosa and lung cancer: Are genetic changes in the oral epithelium associated with lung cancer? // Nigerian J. Clin. Practice. 2017. V. 20. № 1. P. 12–18. https://doi.org/10.4103/1119-3077.181396
  10. Shtivelman E., Hensing T., Simon G.R. et al. Molecular pathways and therapeutic targets in lung cancer // Oncotarget. 2014. V. 5. № 6. P. 1392–1433. https://doi.org/10.18632/oncotarget.1891
  11. Collisson E.A., Campbell J.D., Brooks A.N. et al. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma // Nature. 2014. V. 511. P. 543–550. https://doi.org/10.1038/nature13385
  12. Imielinski M., Berger A.H., Hammerman P.S. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing // Cell. 2012. V. 150. № 6. P. 1107–1120. https://doi.org/10.1016/j.cell.2012.08.029
  13. Rodgers K. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma // Nature. 2018. V. 559. № 7715. https://doi.org/10.1038/s41586018-0228-6
  14. Levy M.A., Lovly C.M., Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm // Genome Res. 2012. V. 22. № 11. P. 2101–2108. https://doi.org/10.1101/gr.131128.111
  15. Drilon A., Wang L., Arcila M.E. et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches // Clin. Cancer Res. 2015. V. 21. № 16. P. 3631–3639. https://doi.org/10.1158/1078-0432.CCR-14-2683
  16. Liu L., Liu J., Shao D. et al. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients // Cancer Sci. 2017. V. 108. № 12. P. 2487–2494. https://doi.org/10.1111/cas.13410
  17. Rooney M., Devarakonda S., Govindan R. Genomics of squamous cell lung cancer // Oncologist. 2013. V. 18. № 6. P. 707–716. https://doi.org/10.1634/theoncologist.2013-0063
  18. Rodgers K. Cancer genome atlas research network. Comprehensive genomic characterization of squamous cell lung cancers // Nature. 2012. V. 489. № 7417. P. 519–525. https://doi.org/10.1038/nature11404
  19. Kim Y., Hammerman P.S., Kim J. et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients // J. Clin. Oncol. 2014. V. 32. № 2. P. 121–128. https://doi.org/10.1200/JCO.2013.50.8556
  20. Wang R., Pan Y., Li C. et al. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas // J. Thorac. Oncol. 2014. V. 9. № 6. P. 760–768. https://doi.org/10.1097/JTO.0b013e3182a406d1
  21. Voortman J., Lee J.H., Killian J.K. et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors // Proc. Natl Acad. Sci. U.S.A. 2010. V. 107. № 29. P. 13040–13045. https://doi.org/10.1073/pnas.1008132107
  22. Imielinski M., Berger A.H., Hammerman P.S. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing // Cell. 2012. V. 150. № 6. P. 1107–1120. https://doi.org/10.1016/j.cell.2012.08.029
  23. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies // Endocrine-Related Cancer J. 2001. V. 8. № 3. P. 161–173. https://doi.org/10.1677/erc.0.0080161
  24. Small D. FLT3 mutations: biology and treatment // Hematology. 2006. V. 1. P. 178–184. https://doi.org/10.1182/asheducation-2006.1.178
  25. Uscanga-Perales G.I., Santuario-Facio S.K., Sanchez-Dominguez C.N. et al. Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico // Oncol. Lett. 2019. V. 17. № 3. P. 3581–3588. https://doi.org/10.3892/ol.2019.9984
  26. Guo M., Tomoshige K., Meister M. et al. Gene signature driving invasive mucinous adenocarcinoma of the lung // EMBO Mol. Med. 2017. V. 9. № 4. P. 462–481. https://doi.org/10.15252/emmm.201606711
  27. Qiu Z., Ye B., Wang K. et al. Unique genetic characteristics and clinical prognosis of female patients with lung cancer harboring RET fusion gene // Sci. Rep. 2020. V. 10. № 10387. https://doi.org/10.1038/s41598-020-66883-0
  28. Zhuo Y.J., Shi Y., Wu T. NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer // Oncol. Lett. 2019. V. 18. № 5. P. 4629–4638. https://doi.org/10.3892/ol.2019.10842
  29. Cebrián A., Gómez Del Pulgar T., Méndez-Vidal M.J. et al. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib // Sci. Rep. 2017. V. 7. № 41371. https://doi.org/10.1038/srep41371
  30. O’Brien T.J., Harralson A.F., Tran T. et al. Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome // Reprod. Biol. Endocrinol. 2014. V. 12. № 36. https://doi.org/10.1186/1477-7827-12-36
  31. Jastania R.A., Saeed M., Al-Khalidi H. et al. Adamantinomatous craniopharyngioma in an adult: A case report with NGS analysis // Int. Med. Case Rep. J. 2020. V. 13. P. 123–137. https://doi.org/10.2147/IMCRJ.S243405
  32. Goriely A., Hansen R.M., Taylor I.B. et al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors // Nat. Genet. 2009. V. 41. № 11. P. 1247–1252. https://doi.org/10.1038/ng.470
  33. Рахимова С.Е., Саматкызы Д., Кожамкулов У.А. и др. Опыт применения панели для секвенирования следующего поколения AmpliSeq Cancer HotSpot v.2 у казахстанских пациентов с плоскоклеточным раком пищевода // Вестник Казахского Нац. Мед. Ун-та. 2020. № 3. С. 76–80.
  34. Tomei S., Adams S., Uccellini L. et al. Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population // Med. Oncol. 2012. V. 29. № 5. P. 3456–3461. https://doi.org/10.1007/s12032-012-0255-3
  35. Jin M., Li Z., Sun Y. et al. Association analysis between the interaction of RAS family genes mutations and papillary thyroid carcinoma in the Han Chinese population // Int. J. Med. Sci. 2021. V. 18. № 2. P. 441–447. https://doi.org/10.7150/ijms.50026
  36. Testa U., Castelli G., Pelosi E. Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells // Cancers (Basel). 2018. V. 10. № 8. https://doi.org/10.3390/cancers10080248
  37. Mogi A., Kuwano H. TP53 Mutations in nonsmall cell lung cancer // J. Biomedicine and Biotechnology. 2011. V. 2011. № 583929. https://doi.org/10.1155/2011/583929
  38. Tao D., Han X., Zhang N. et al. Genetic alteration profiling of patients with resected squamous cell lung carcinomas // Oncotarget. 2016. V. 7. № 24. P. 36590–36601. https://doi.org/10.18632/oncotarget.9096
  39. Scheffler M., Bos M., Gardizi M. et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies // Oncotarget. 2015. V. 6. № 2. P. 1315–1326. https://doi.org/10.18632/oncotarget.2834
  40. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy // Nat. Reviews. Drug Discovery. 2013. V. 8. № 3. P. 235–253. https://doi.org/10.1038/nrd2792
  41. Jing P., Zhao N., Xie N. et al. miR-24-3p/FGFR3 signaling as a novel axis Is involved in epithelial-mesenchymal transition and regulates lung adenocarcinoma progression // J. Immunol. Res. 2018. V. 2018. № 2834109. https://doi.org/10.1155/2018/2834109
  42. Gasche C., Chang C.L., Rhees J. et al. Oxidative stress increases frameshift mutations in human colorectal cancer cells // Cancer Research. 2001. V. 61. P. 7444–7448.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Frequency of mutations in blood (a) and buccal epithelium (b) of healthy individuals and patients with lung cancer. * - p < 0.05, differences in frequency of occurrence according to Pearson's χ2 are statistically reliable

Download (209KB)
Indexing metadata
3. Fig. 2. Frequency of mutations in blood and buccal epithelium of patients with lung cancer. * p < 0.05, differences in frequency of occurrence according to Pearson's χ2 are statistically reliable

Download (109KB)
Indexing metadata
4. Fig. 3. Number of different types of mutations in buccal epithelium and blood in patients with lung cancer

Download (299KB)
Indexing metadata

Copyright (c) 2024 Russian Academy of Sciences